Skip to main content
Caplight Logo









AusperBio

AusperBio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://ausperbio.com/

Last Round

Series C

Aug 27, 2026

Total Funding Raised

$356.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

AusperBio is a biopharmaceutical company that develops targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B and other liver diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antisense oligonucleotideASOchronic hepatitis BCHBbiopharmaceuticaldrug developmentclinical trialsinfectious disease therapybiotechdrug discoveryviral replicationfunctional cureclinical-stage biotechtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AusperBio Comparables

Compare AusperBio with similar companies based on industry and business-model similarity.

AusperBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mirum Pharmaceuticals
83%
Arbutus Biopharma Corp
79%
Aligos Therapeutics
78%

AusperBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 27, 2026
Series B ExtensionSep 21, 2025
Series B ExtensionMay 28, 2025
Series BDec 26, 2024
Series AJul 14, 2024
Seed
Nov 7, 2023

AusperBio Investors

Notable investors and investment history

AusperBio investors
InvestorRounds
CDH InvestmentsSeries B Extension, Series B
RA Capital ManagementSeries C
Genesis CapitalSeries B Extension
YuanBio Venture CapitalSeries B Extension, Series B, Series A, Series C
Genesis CapitalSeries B Extension, Series A
Sherpa CapitalSeries B Extension, Series B
Sherpa CapitalSeries B Extension, Series B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 27, 2026

    $120M round with participation from CDH Investments and Hankang Capital.

  • Jul 26, 2026

    Monthly visitors increased 168% MoM.

AusperBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AusperBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AusperBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range10
Year Founded2019
Last FundingAug 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?